Boserolimab: Clinical Trials

2 trials of Boserolimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 1, Recruiting 1
Phase 21Recruiting 1

Follow Boserolimab: new trials by email Literature Review of Boserolimab trials Research Report on Boserolimab

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Pembrolizumab, Carboplatin, Paclitaxel - Carcinoma, Non-Small-Cell Lung
Phase 1 / Phase 2RecruitingMerck Sharp & Dohme LLC4502019-12-192026-10-29
Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
Boserolimab, Pembrolizumab, Pemetrexed - Pharmacokinetics, Solid Tumor
Phase 1CompletedMerck Sharp & Dohme LLC1822018-02-182025-11-05

Conditions studied

Carcinoma, Non-Small-Cell Lung (2)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (2)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

Merck Sharp & Dohme LLC (2)

Countries

Israel (2)  ·  South Korea (2)  ·  Spain (2)  ·  Taiwan (2)  ·  United States (2)  ·  Canada (1)  ·  Chile (1)  ·  Hungary (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Ukraine (1)

NIH funding

2017 (1), 2023 (1)